TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02735044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine,300 U/mL
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter \[mmol/L\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (100 units /mL)
Description: Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Fast-acting mealtime insulin analogs
Study: NCT03637114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask
Study: NCT00767637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (BAY77-1931)
Description: BAY77-1931 750mg, in the morning, day and evening
Study: NCT03009578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Injection
Description: iron Intramuscular injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Bisglycinate
Description: oral iron tablets
Study: NCT00313378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypothetica

Intervention type: DRUG
Group type: OTHER
Intervention: Hypothetica
Study: NCT01647620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPOC-4088
Description: A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 10-day oral dosing of matching placebo prolonged release tablet.
Study: NCT03158116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Aztreonam
Description: Inhaled antibiotic with anti-pseudomonal properties
Study: NCT02260700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
Study: NCT04579536

Intervention type: OTHER
Group type: OTHER
Intervention: Vanish White Varnish
Description: 5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
Study: NCT01180036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
Study: NCT01404559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ossur Variflex prosthetic foot
Description: Lightweight energy-storing prosthetic foot

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ossur Ceterus prosthetic foot
Description: Shock-absorbing prosthetic foot

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endolite Elite Blade prosthetic foot
Description: Multi-axial prosthetic foot
Study: NCT03924219

Intervention type: OTHER
Intervention: CMV T cell Immunity Assay
Description: Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
Study: NCT03549572

Intervention type: BEHAVIORAL
Intervention: Coma Recovery Scale-Revised
Description: Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
Study: NCT04428788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-94676
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC1083611
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC1083610
Description: Specified dose on specified days
Study: NCT03625869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCSO
Description: After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
Study: NCT02405247

Intervention type: OTHER
Intervention: Patient Reported Outcome (PRO)
Description: Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
Study: NCT02713984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-HER2 CAR-T
Description: HER-2-targeting CAR-T cells infusion in HER2 positive cancers
Study: NCT03636672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perturbation training
Description: perturbation training during stationary bicycle riding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: perturbation training during stationary bicycle riding
Study: NCT02323126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: EGF816 150 mg once daily (QD) administered orally as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 400 mg twice daily (BID) administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 400 mg twice daily (BID) administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
Study: NCT01741233

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VitDgen
Study: NCT00858728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 portions
Description: Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 2 portions
Description: Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
Study: NCT01152593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Intranasal cream given to patient after confirmation of colonization
Study: NCT01168830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMS-3.0
Study: NCT01066104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xolair placebo
Description: two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair (omalizumab)
Description: two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
Study: NCT04660552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
Study: NCT03928418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person counseling session
Description: Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person counseling session
Description: Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live phone call booster session
Description: Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology (IVR or SMS) booster session
Description: Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
Study: NCT01399151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D - Treatment 1
Description: Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D - Treatment 2
Description: Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
Study: NCT02260700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment A)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
Study: NCT01399151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D - Treatment 3
Description: Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
Study: NCT03668470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide 1.5mg : One injection per week during 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: one injection per week during 24 weeks
Study: NCT02260700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment B)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (Treatment C)
Description: Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
Study: NCT02735044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy
Description: Fast-acting mealtime insulin analogs
Study: NCT00387023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m\^2 IV over 4-6 hours for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: 5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
Study: NCT04322266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1701
Description: Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1701
Description: Ezetimibe / Rosuvastatin / Amlodipine / Losartan potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Ezetimibe /Rosuvastatin
Study: NCT00964002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Study: NCT01828606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coban 2 system
Description: All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coban 2 system
Description: All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place
Study: NCT04322266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Description: Ezetimibe /Rosuvastatin
Study: NCT01828606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coban lite system
Description: All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coban lite system
Description: All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place
Study: NCT00487942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 50 mg/day armodafinil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 100 mg/day armodafinil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 200 mg/day armodafinil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04875377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reformulated pizza
Description: Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control pizza
Description: Control (placebo) meal to consume thrice weekly (no iodine supplementation).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed capsule
Description: Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control capsule
Description: Empty capsules (placebo)
Study: NCT03263910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPO-11
Description: 20 ml NPO-11

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml NPO-11(Placebo)